MTOR and non-small cell lung carcinoma: TKI resistance can arise through aberrant activation of the PI3K/AKT/mTOR axis in several cancer types, including NSCLC, often through PTEN deletion [50] or activating PIK3CA mutations [51]; however, such mechanisms were elucidated primarily in the context of EGFR inhibitors.